• OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Korea Health Industry Development Institute.
• The Company signed an MOU with DynamiCure Biotechnology to develop an ADC immunotherapy using RNA technology.

The Ministry of Health and Welfare of Korea and Korea Health Industry Development Institute hosted Korea-US Digital·BioHealth Business Forum on April 27 in Boston. OliX took part in the forum as it was selected as one of the five Korean companies to sign a collaboration agreement with a U.S. company. At the event, OliX inked an MOU with DynamiCure to agree on innovative technological collaboration for developing RNA-ADC therapeutics.

DynamiCure Biotechnology specializes in developing oncology drugs and autoimmune therapies with antibody technology. The company owns an anticancer pipeline, which is currently in the clinical stage, with a mechanism of targeting a receptor that affects the abnormal development of tumor vasculature.

Meanwhile, Dong Ki Lee, Ph.D., Founder and Chief Executive Officer of OliX Pharmaceuticals, was selected as one of the business delegation members and accompanied South Korean President Yoon Suk Yeol on his state visit to the U.S. While staying in the U.S., Dr. Lee participated in official occasions including the Korea-U.S. Advanced Industry Forum hosted by the U.S. Chamber of Commerce, and the official welcoming ceremony held by the U.S. government at the White House.